# Safety of HRX215 in Patients After Minor and Major Liver Resection

> **NCT06638502** · PHASE1,PHASE2 · RECRUITING · sponsor: **HepaRegeniX GmbH** · enrollment: 80 (estimated)

## Conditions studied

- Liver Resection
- Colorectal Carcinoma Liver Metastases

## Interventions

- **DRUG:** HRX215 capsules
- **DRUG:** Placebo capsules

## Key facts

- **NCT ID:** NCT06638502
- **Lead sponsor:** HepaRegeniX GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-06
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06638502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06638502, "Safety of HRX215 in Patients After Minor and Major Liver Resection". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06638502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*